RCEL AVITA Medical, Inc.
FY2025 10-K
AVITA Medical, Inc. (RCEL) filed its fiscal year 2025 10-K annual report with the SEC on Feb 12, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Multi-product acute wound care platform focused on autologous cell harvesting technology RECELL plus complementary wound matrices
- • New products: Commercial launch of Cohealyx collagen dermal matrix (Apr 2025) and FDA approval/commercial rollout of RECELL GO mini for smaller wounds (Dec 2024)
Management Discussion & Analysis
- • Revenue $71.6M in 2025, up 11% YoY from $64.3M in 2024, driven by deeper penetration and new accounts
- • Gross margin 82.1% in 2025 vs 85.8% in 2024; decrease due to product mix and higher inventory reserve
Risk Factors
- • Regulatory risk: dependency on FDA PMA for RECELL, risk of modification/suspension/revocation impacting U.S. operations
- • Macroeconomic risk: $60M five-year senior secured credit facility with Perceptive, subject to net revenue covenants and rising interest rate exposure
Financial SummaryXBRL
Revenue
$72M
Net Income
-$49M
Gross Margin
82.1%
Operating Margin
-59.4%
Net Margin
-67.8%
ROE
291.8%
Total Assets
$56M
EPS (Diluted)
$-1.74
Operating Cash Flow
-$31M
Source: XBRL data from AVITA Medical, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on AVITA Medical, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.